Close
Close
Tesamorelin

Tesamorelin 3-Month Membership Program

Price range: $2,400.00 through $3,000.00

4.9 Avg. Rating

1000+ Reviews

  • Follow-up Exam
  • Lab Review
  • Dose Adjustments
  • Certificate of Authenticity
  • 503A Pharmacies
  • 99% Pure
  • US-based Peptides
Tesamorelin is a peptide that many patients ask about when they’re interested in supporting healthy body composition, particularly around reducing certain types of stubborn abdominal fat. It stands out among many peptides discussed in wellness settings because it actually carries FDA approval for a specific medical use, which gives it a distinctive place in this category.
Tesamorelin is a synthetic version of a hormone your body already produces called growth hormone-releasing hormone, or GHRH. It’s designed to prompt your pituitary gland, a small gland at the base of the brain, to release its own growth hormone in a natural, pulsing pattern, similar to how your body would normally regulate growth hormone release on its own.
Patients commonly ask about Tesamorelin because it holds FDA approval specifically for reducing excess abdominal fat in people with a condition called HIV-associated lipodystrophy, a syndrome involving abnormal fat distribution sometimes seen in people being treated for HIV. Beyond this specific approved use, Tesamorelin has also drawn interest from patients and providers exploring its potential role in supporting visceral fat reduction and growth hormone-related wellness more broadly, though this broader use is considered off-label.
It’s important to understand this distinction clearly: Tesamorelin’s approval is specific and narrow, even though its underlying mechanism, supporting natural growth hormone release, is relevant to a wider range of patient goals. This page will walk through both the approved use and the broader research context so you can have an informed conversation with your provider.
To understand how Tesamorelin works, picture your pituitary gland like a factory that produces growth hormone, and picture GHRH as the “start production” message your brain normally sends to that factory. Tesamorelin is designed to deliver essentially that same message, prompting the pituitary gland to release its own growth hormone in a natural, pulsing pattern, rather than supplying growth hormone directly. Because growth hormone plays a role in metabolizing fat, particularly a type of fat that surrounds internal organs called visceral fat, supporting its natural release is part of why Tesamorelin has been studied for reducing this specific type of fat accumulation. This is different from general weight loss; Tesamorelin’s approved effect is specifically on visceral fat, and it’s officially described as weight-neutral, meaning it doesn’t necessarily change your overall body weight. Because Tesamorelin works with your body’s own natural growth hormone signaling and pulsing pattern, rather than replacing the hormone directly, some patients and providers consider it a more physiologic approach compared to direct growth hormone therapy.
  • Is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, based on rigorous Phase III clinical trial data
  • May help support reduction of visceral fat more broadly, based on the same underlying mechanism, though this broader use remains off-label and less extensively studied outside the approved population
  • May help promote healthy growth hormone-related metabolism, supporting the body’s own natural growth hormone pulsing pattern
  • Has shown promise in research related to liver fat content in certain populations, an area of ongoing study
  • May assist with body composition goals as part of a broader, medically guided wellness plan
Individual results vary, and Tesamorelin’s strongest, most rigorously proven benefit remains specific to its FDA-approved population; broader use should be discussed carefully with your provider.
Patients who commonly ask about Tesamorelin include those interested in:
  • Body composition support, particularly patients interested in visceral fat reduction
  • Healthy aging, for patients noticing age-related changes in body composition and growth hormone levels
  • Wellness optimization, for patients working with a provider on a broader metabolic and vitality plan
  • HIV-associated lipodystrophy, the specific population for which Tesamorelin carries FDA approval
This therapy is not appropriate for everyone. Long-term cardiovascular safety data outside the approved population has not been fully established, and it should never be started without a proper medical evaluation. A licensed provider will review your health background to determine if this option makes sense for you.
Tesamorelin has one of the more robust human clinical trial foundations among the peptides discussed on this site. Its FDA approval was based on randomized, placebo-controlled Phase III trials involving hundreds of participants with HIV-associated lipodystrophy, which found meaningful reductions in visceral adipose tissue, along with improvements in certain related markers like triglycerides, compared to placebo. Beyond the approved population, researchers have also studied Tesamorelin’s effects on liver fat content, including research suggesting it may help reduce liver fat and related markers of liver inflammation in specific populations. Additional research has looked at Tesamorelin’s effects on cognitive function in some populations, an area that remains under investigation. It’s important to be transparent that while Tesamorelin’s approved indication is well supported by rigorous clinical trial evidence, its use for general body composition or healthy aging purposes in people without HIV-associated lipodystrophy is considered off-label, and the FDA has specifically noted that long-term cardiovascular safety data has not been established for this medication. Research in these broader populations continues to evolve, and individual responses vary.
Tesamorelin’s most commonly reported side effects, based on its FDA-approved clinical trial data, include joint discomfort, pain in the extremities, swelling, muscle aches, and injection site reactions. Because it works through the growth hormone pathway, it requires careful consideration in certain patients. Tesamorelin should be used with particular caution in patients with active cancer, since growth hormone and related growth factors can theoretically support the growth of certain tumors, an important consideration your provider will discuss during your evaluation. The FDA has also noted that long-term cardiovascular safety has not been established, so your provider will weigh the risks and benefits of continued treatment based on your individual response. This is not a complete list of contraindications, and only a licensed provider reviewing your full medical history can determine whether Tesamorelin is safe and appropriate for you. Medical supervision matters throughout the entire course of treatment, not just at the start. Following your prescribed dosing schedule, attending follow-up appointments, and reporting any side effects to your provider are all important parts of using this therapy safely and effectively.

What does Tesamorelin do?

Tesamorelin prompts your pituitary gland to release its own growth hormone, which is specifically FDA-approved to help reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.

Is Tesamorelin FDA-approved?

Yes, specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Use for general body composition or healthy aging purposes outside this population is considered off-label.

How long before I may notice changes?

In clinical trials, meaningful reductions in visceral fat were generally observed over 26 to 52 weeks of treatment, and individual responses vary.

Is it an injection?

Yes, Tesamorelin is administered as a subcutaneous injection, and your provider will walk you through proper technique and scheduling.

Can it be combined with other peptides?

In some cases, providers combine Tesamorelin with other peptides, such as Ipamorelin, as part of an individualized treatment plan. This decision should always be made with your provider.

Can it be combined with GLP-1 medications?

Some patients use Tesamorelin alongside GLP-1 medications as part of a broader body composition plan. Your provider can discuss whether this combination fits your individual situation.

Will I need lab work?

Your provider may review existing labs or recommend baseline and follow-up lab testing to help guide your treatment plan and monitor your progress.

Who should avoid this peptide?

Patients with active cancer should have a particularly careful conversation with their provider, given growth hormone’s theoretical relationship to tumor growth. A full medical evaluation will help determine appropriateness.

How long do patients typically remain on therapy?

Treatment plans are individualized, but many programs are structured around a three-month cycle with a comprehensive follow-up to reassess progress and goals.

Is a consultation required?

Yes. A telehealth consultation with a licensed medical provider is required before starting Tesamorelin or any peptide therapy at SevenHealth.
Every peptide treatment program at SevenHealth is built around comprehensive, individualized medical care. When you begin therapy, your program includes:
  • An initial telehealth medical history and comprehensive evaluation with a licensed medical provider
  • Review of previous laboratory results when available, or recommendations for laboratory testing when medically appropriate
  • Personalized treatment recommendations based on your medical history and goals
  • Three months of prescribed peptide therapy when medically appropriate
  • A customized dosing and titration schedule specific to your prescribed peptide
  • A comprehensive follow-up appointment approximately three months after starting treatment
  • Review of progress, discussion of results, treatment adjustments if medically appropriate, and continued provider guidance
  • Ongoing provider oversight throughout your treatment program
  • No additional fees for appointments included within the treatment program
  • No additional fees for laboratory review as part of your treatment
Our goal is to make your experience with peptide therapy simple, transparent, and medically supervised from your very first consultation through every follow-up appointment. You will always know what to expect, what you’re paying for, and who to reach out to with questions along the way.
Patients choose SevenHealth because we focus on individualized, medically supervised care rather than one-size-fits-all protocols. Every treatment plan is built around your specific health history and goals, and every prescription is overseen by a licensed medical provider from start to finish. We work with FDA-registered 503A U.S. compounding pharmacies that follow applicable quality standards, so you can feel confident in the source and handling of your prescribed peptide therapy. Dosing is guided by your provider, not guesswork, and every program includes a three-month follow-up to review your progress and make adjustments if needed. We also believe in transparent pricing. There are no surprise appointment fees or lab review fees hidden within your treatment program, so you always know what you’re paying for.
  • Tesamorelin is a synthetic GHRH analog that prompts your pituitary gland to release its own growth hormone.
  • It carries FDA approval specifically for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
  • Use for general body composition or healthy aging purposes outside this population is considered off-label.
  • Clinical trial evidence supporting the approved use is well established, including meaningful reductions in visceral fat and improved triglycerides.
  • Long-term cardiovascular safety has not been established, which your provider will factor into your treatment plan.
  • Patients with active cancer should have a particularly careful conversation with their provider before starting.
  • Common side effects include joint discomfort, injection site reactions, and swelling.
  • SevenHealth includes an initial evaluation, personalized dosing, lab review, and a three-month follow-up in every treatment program.

Educational Disclaimer

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapy should only be used under the supervision of a licensed healthcare provider after an appropriate medical evaluation. Individual results may vary.

$100 OFF GLP-1 Injectable Plans for New Members ! CODE: